Spotline V-Assure Platform Enables Pre-Validation for Veeva Basics Releases
SAN JOSE, Calif., May 20, 2025 /PRNewswire/ -- Spotline, Inc., a Veeva-certified product, services, and AI partner, today announced that Veeva Systems is using its V-Assure platform to enable faster, pre-validated software releases for Veeva Basics—the pre-configured solution designed to help emerging biotechs achieve rapid deployment and built-in GxP compliance.
Veeva used Spotline's V-Assure platform to accelerate the delivery of the last three releases of Veeva Basics for clinical, regulatory, and quality. V-Assure automated testing for these applications, providing emerging biotech customers with documentation to support the Basics Production Qualification.
How Spotline Supports Veeva Basics' Mission for Biotech Speed and Compliance
To help Veeva deliver Veeva Basics efficiently as a turnkey application, Spotline:
This proactive, automation-first approach helped ensure that every release was audit- and inspection-ready to support accelerated development and release management of Veeva Basics.
'By using Spotline's V-Assure testing platform, we can deliver complete qualification documentation across our Veeva Basics applications,' said Steve Harper, General Manager of Veeva Basics. 'Automating testing helps us to move faster and provide testing and documentation on behalf of our customers. This saves time and effort while accelerating application delivery for emerging biotech.'
Automated Validation Across Veeva Basics Applications
With Spotline's V-Assure one-touch automated testing within each release cycle, Veeva successfully delivered audit- and inspection-ready validation documentation for its Veeva Basics applications in clinical, regulatory, and quality. Through the validation process, Veeva automated more than 500 test case executions across its Veeva Basics applications.
'Supporting the Veeva Basics team through three major releases has showcased how automated validation—when done right—can deliver speed and reliability,' said Sid Sahoo, CEO of Spotline, Inc. 'V-Assure is helping life sciences organizations modernize their validation processes and unlock faster adoption of compliant solutions.'
Meet Us at the Veeva R&D and Quality Summits
Spotline will demonstrate the latest version of V-Assure, including its enhanced integrations with Veeva Validation Management, at the upcoming Veeva R&D and Quality Summits in Europe and the U.S.
Attendees are encouraged to schedule a demo at www.spotline.com/v-assure to explore how V-Assure can transform their validation operations.
About Spotline Inc.
Spotline Inc. is a Veeva-certified partner delivering innovative validation, automation, and integration solutions for life sciences. Through products like V-Assure, Spotline enables biotech and pharmaceutical companies to accelerate compliance, reduce risk, and focus on strategic innovation.
For more information about Spotline, please visit www.spotline.com
Contact Info
Jeff Andrist
Spotline Inc.
Email: [email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/spotline-v-assure-platform-enables-pre-validation-for-veeva-basics-releases-302459936.html
SOURCE Spotline, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
35 minutes ago
- Wall Street Journal
Wholesale Inflation Undershot Forecasts in May
Wholesale inflation undershot expectations last month, according to a Labor Department report that came a day after a weaker-than-forecast reading on consumer prices. Producer prices rose 0.1% in May from April, below the 0.2% rise economists polled by The Wall Street Journal had expected. Over the past 12 months, the producer-price index rose 2.6%, slightly above April's revised figure.
Wall Street Journal
39 minutes ago
- Wall Street Journal
RH Swings to Surprise Profit Despite Tariff Pressures
RH swung to a profit in its fiscal first quarter despite the impact of tariffs on spending and the shakiest housing market in decades, pushing its shares higher after hours. The furniture retailer posted a profit of $8 million, or 40 cents a share, for the quarter ended May 3. That stacks against a loss of $3.6 million, or 20 cents a share, in the comparable quarter a year earlier. Analysts polled by FactSet had been expecting another loss.
New York Times
an hour ago
- New York Times
Trump Shifts Deportation Focus, Pausing Raids on Farms, Hotels and Eateries
The Trump administration has abruptly shifted the focus of its mass deportation campaign, telling Immigration and Customs Enforcement officials to largely pause raids and arrests in the agricultural industry, hotels and restaurants, according to an internal email and three U.S. officials with knowledge of the guidance. The decision suggested that the scale of President Trump's mass deportation campaign — an issue that is at the heart of his presidency — is hurting industries and constituencies that he does not want to lose. The new guidance comes after protests in Los Angeles against the Trump administration's immigration raids, including at farms and businesses. It also came as Mr. Trump made a rare concession this week that his crackdown was hurting American farmers and hospitality businesses. The guidance was sent on Thursday in an email by a senior ICE official, Tatum King, to regional leaders of the ICE department that generally carries out criminal investigations, including work site operations, known as Homeland Security Investigations. 'Effective today, please hold on all work site enforcement investigations/operations on agriculture (including aquaculture and meat packing plants), restaurants and operating hotels,' he wrote in the message. The email explained that investigations involving 'human trafficking, money laundering, drug smuggling into these industries are OK.' But it said — crucially — that agents were not to make arrests of 'non-criminal collaterals,' a reference to people who are undocumented but who are not known to have committed any other crime. Want all of The Times? Subscribe.
